{
  "id": 18132651,
  "title": "Climb Bio to present budoprutug ITP trial data at ASH meeting",
  "url": "https://urgent.news/2026/11/04/climb-bio-to-present-budoprutug-itp-trial-data-at-ash-meeting",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-04T14:20:43.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/climb-bio-to-present-budoprutug-itp-trial-data-at-ash-meeting-93CH-4999823"
  },
  "original_language": "en",
  "account": "Climb Bio, a clinical-stage biotech company, will showcase budoprutug data for immune thrombocytopenia at the upcoming ASH meeting. The Phase 1b trial evaluated budoprutug, an anti-CD19 monoclonal antibody, in patients with a history of primary ITP. Three dose cohorts were studied, with safety, B-cell depletion, and platelet results presented at a poster session. Budoprutug targets CD19-expressing B cells. Climb Bio is developing other treatments for immune-mediated diseases, including CLYM116 for IgA nephropathy.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}